Synopsis
We endeavored to investigate outcomes associated with use of multiple neurostimulation modalities as compared with conventional SCS settings alone in a prospective, randomized controlled trial. The primary endpoint was proportion of subjects permanently implanted with an SCS system capable of multiple neurostimulation modalities demonstrating 50% or greater reduction in average overall pain intensity at 3-months post-randomization. The study met its primary endpoint based on a pre-specified cohort of 89 randomized subjects (p<0.001). The results provide further support for the advantages of using neuromodulation systems capable of patient-specific stimulation options that enable highly customized therapy for treatment of chronic pain.
Disclosures
Display Label | Action |
---|---|
Abstract - NPC2021 Wallace COMBO 2021 | Download Abstract |
Poster - NPC2021 Wallace COMBO 2021 | Download Poster |
Synopsis
We endeavored to investigate outcomes associated with use of multiple neurostimulation modalities as compared with conventional SCS settings alone in a prospective, randomized controlled trial. The primary endpoint was proportion of subjects permanently implanted with an SCS system capable of multiple neurostimulation modalities demonstrating 50% or greater reduction in average overall pain intensity at 3-months post-randomization. The study met its primary endpoint based on a pre-specified cohort of 89 randomized subjects (pxtagstartz0.001). The results provide further support for the advantages of using neuromodulation systems capable of patient-specific stimulation options that enable highly customized therapy for treatment of chronic pain.